Adaptive Biotechnologies (ADPT) vs Kodiak Sciences (KOD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kodiak Sciences (KOD) has outperformed Adaptive Biotechnologies (ADPT) over the past year, gaining 540.1% versus a gain of 83.1%. Over five years, KOD leads with a -18.7% price change compared with -21.6% for ADPT. Kodiak Sciences is the larger company by market cap ($5.92 billion vs $4.16 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | KOD |
|---|---|---|
| Share price | $26.09 | $94.26 |
| Market cap | $4.16B | $5.92B |
| 1-day change | -0.72% | +3.49% |
| YTD return | +61.82% | +225.75% |
| 1-year return | +83.14% | +540.06% |
| 5-year return | -21.55% | -18.66% |
| EPS (TTM) | $-0.41 | $-4.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | — |
| Revenue growth (YoY) | +54.77% | — |
| Net income (latest FY) | $-59.50M | $-229.97M |
| Gross margin | 74.24% | — |
| Operating margin | -20.62% | — |
| Net margin | -21.48% | — |
| 52-week high | $30.74 | $104.00 |
| 52-week low | $12.00 | $10.94 |
| Distance from 52-week high | -15.13% | -9.37% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +8.51% | +23.77% |
| Average volume | 2.38M | 1.56M |
| Shares outstanding | 159.60M | 62.85M |
| Employees | 624 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed ADPT by 456.9 percentage points over the past year.
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
ADPT vs KOD FAQ
Which is bigger, Adaptive Biotechnologies or Kodiak Sciences?
Kodiak Sciences (KOD) is larger, with a market capitalization of $5.92B compared with $4.16B for Adaptive Biotechnologies (ADPT).
Which stock has performed better over the past year, ADPT or KOD?
KOD returned +540.06% over the past 12 months, compared with +83.14% for ADPT (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and Kodiak Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.